Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT00002939
Phase
PHASE1
Status
Completed

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan and paclitaxel in treating patients with metastatic or recurrent cancer.

Key Dates

Start date
Nov 30, 1996
Status verified
Sep 2013
Primary completion
Feb 28, 2001
Completion
Apr 30, 2002

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Paclitaxel in combination with Irinotecan
    The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.

Primary Outcome Measure

Determine the maximum tolerated dose [ Time Frame: 3 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Chicago Cancer Research CenterChicagoIllinois60637-

Find similar trials in Chicago, IL

By research site
University of Chicago Cancer Research Center· Chicago, IL

Related Studies